Hoba, a Danish biotech from Novo, raises $25M to crack into difficult pain and hearing loss fields Novo Holdings-founded biotech Hoba Therapeutics has raised $25 million in the first close of a Series A financing to bankroll its investigational medicines for pain and hearing loss. Copenhagen-based Hoba, which got its start about seven years ago after acquiring IP from NeuroSearch spinoff NsGene, has a non-opioid candidate that it hopes could follow in the footsteps of Vertex Pharmaceuticals’ leading program. Boston-based Vertex is on the verge of a late-stage readout for its candidate VX-548 for acute pain. Unlock this article instantly by becoming a free subscriber. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
This content was originally published here.